Bruker Corporation (BRKR)
SuperavaliadaFundamental
33
Preço
$64.75
Capitalização de Mercado
$9.87B
Parte 1 · Quanto vale a empresa
Visão Geral
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 de setembro de 2026 with claude-haiku-4-5 — shared with all users
Named by Bruker in its own 10-K, Thermo Fisher sells mass spectrometers, molecular spectroscopy and electron microscopy systems to the same pharmaceutical, academic and industrial laboratories Bruker serves worldwide.
Agilent competes head-on in mass spectrometry, chromatography coupling and molecular spectroscopy for life-science and applied-chemistry labs, the core of Bruker's CALID business.
Waters sells LC-MS platforms to the same pharmaceutical QC, proteomics and food-safety customers that buy Bruker's timsTOF and triple-quadrupole instruments.
Through SCIEX and Leica Microsystems, Danaher bids against Bruker for the same mass-spectrometry and high-end microscopy budgets in research and clinical laboratories.
Shimadzu offers a full analytical-instrument catalogue — mass spectrometry, spectrophotometry, surface analysis — and is Bruker's main Japanese rival in Asian academic and industrial accounts.
JEOL is the main alternative supplier of NMR and electron-microscopy systems, the market where Bruker's BioSpin division holds its strongest position.
Balanço & Liquidez
Receita
$3.50B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$-71M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$43M
Capital Próprio Total
$2.46B
Passivo Total
$3.73B
Rácio de Liquidez
1.85
Cobertura de Juros
0.50
Dívida/EBITDA
6.33
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$46.11
Preço Atual
$64.75
Margem de Segurança
-40.4%
Intervalo de Valor Justo
$29.97 - $62.25
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
-
ROE
-0.4%
Rácio P/B
4.11
P/FCF
105.06
Margem Bruta
46.4%
ROIC
-0.5%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
-0.5%
WACC
10.0%
ROIC − WACC
-10.5 pp
O ROIC está abaixo do custo do capital — a empresa está a destruir valor a cada dólar investido.
Critérios de Análise Fundamental
Aprovado (10)
- Price CAGR 10.91%
- Gross Margin 46.4%
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 11.6%
- Analyst Consensus 62% Buy
- Earnings Surprise avg 19.0%
- Share Dilution -61.5%
- Piotroski F-Score 5/9
Reprovado (13)
- EPS shows upward trend
- ROIC -0.5%
- P/FCF 105.06
- P/B Ratio 4.11
- Operating Margin -0.9%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Overvalued)
- ROE -2.9%
- Net Margin Trend -2.0% vs 2.3%
Indisponível (4)
- Dividend Payout NaN%
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Sinais mistos: algumas áreas requerem atenção
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
A recomprar ações. Favorável ao acionista
Participações institucionais
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Dr. Frank H. Laukien Ph.D. | Chairman, CEO & President | 65 |
| Mr. Gerald N. Herman CPA | Executive VP & CFO | 67 |
| Dr. Mark R. Munch Ph.D. | Corporate Executive VP and President of Bruker Nano Group & Corporate | 63 |
| Mr. Juergen W. Srega | President of Bruker Biosystems Group & Bruker Daltonics Division | 70 |
| Mr. Thomas M. Bures | Chief Accounting Officer | 50 |
| Mr. J. Brent Alldredge J.D. | Senior VP, General Counsel, Secretary & Global Head of Compliance | 50 |
| Dr. Wolfgang Pusch Ph.D. | President of Bruker Microbiology & Infection Diagnostics Group | - |
| Dr. Burkhard Prause Ph.D. | President and CEO of Bruker Energy & Supercon Technologies, Inc. | 58 |
Risco de Auditoria
7
Risco do Conselho
6
Risco de Remuneração
6
Risco dos Direitos dos Acionistas
5
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Documentos
- Ver documento
Relatório anual (10-K)
Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.
Arquivado em 2026-02-27
- Ver documento
Relatório trimestral (10-Q)
Uma atualização sobre o desempenho financeiro dos últimos três meses.
Arquivado em 2026-08-05
- Ver documento
Relatório de fato relevante (8-K)
Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.
Arquivado em 2026-08-14
via SEC EDGAR
Histórico de Resultados
via SEC EDGAR
Latest News
Recent headlines for BRKR, sourced from Markets Gazette.